The University of Southampton
University of Southampton Institutional Repository

Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy

Record type: Article

Background. In multiple myeloma, expression of cancer testis antigens may provide prognostic markers and potential targets for immunotherapy. Expression at relapse has not yet been evaluated for a large panel of cancer testis antigens, which can be classified by varying expression in normal tissue: restricted to testis, expressed in testis and brain and not restricted but selectively expressed in testis.

Design and Methods. Evaluation of cancer testis antigen expression was performed in newly diagnosed multiple myeloma cases (HOVON-65/GMMG-HD4 trial; n=320) and in relapse cases (APEX, SUMMIT, CREST trials; n=264). Presence of expression using Affymetrix GeneChips was determined for 123 cancer testis antigens, of which 87 had a frequency of more than 5% in the newly diagnosed and relapsed patients and were evaluated in detail.

Results. For 58 out of 87 cancer testis antigens tissue restriction was known. A significantly lower frequency of presence calls in the relapsed compared to newly diagnosed cases was found for 3 out of 13 testis restricted genes, 2 out of 7 testis/brain restricted genes and 17 out of 38 testis selective genes. MAGEC1, MAGEB2 and SSX1 were the most frequent testis-restricted cancer testis antigens in both data sets. Multivariate analysis demonstrated that presence of MAGEA6 and CDCA1 were clearly associated with shorter progression free survival, and presence of MAGEA9 with shorter overall survival in the set of newly diagnosed cases. In the set of the relapse cases, presence of CTAG2 was associated with shorter progression free survival and presence of SSX1 with shorter overall survival.

Conclusions. Relapse multiple myeloma reveals extensive cancer testis antigen expression. Cancer testis antigens are confirmed as useful prognostic markers in newly diagnosed MM patients and in relapse MM patients. The HOVON-65/GMMG-HD4 trial is registered under Dutch trial register nr NTR-213. CREST, SUMMIT and APEX trials were registered under numbers M34100-024, M34100-025 and NCT00049478/ NCT00048230, respectively.

Full text not available from this repository.

Citation

van Duin, Mark, Broyl, Annemiek, de Knegt, Yvonne, Goldschmidt, Hartmut, Richardson, Paul G., Hop, Wim C.J., van der Holt, Bronno, Joseph-Pietras, Debora, Mulligan, George, Neuwirth, Rachel, Sahota, Surinder S. and Sonneveld, Pieter (2011) Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy Haematologica, 96, (11), pp. 1662-1669. (doi:10.3324/haematol.2010.037978). (PMID:21791470).

More information

Published date: November 2011
Keywords: multiple myeloma, cytogenetics and molecular genetics, cancer testis antigen, genechip, gene expression
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 195639
URI: http://eprints.soton.ac.uk/id/eprint/195639
ISSN: 0390-6078
PURE UUID: 4b0e4fdb-7d06-40d2-91ab-bbf47063d114

Catalogue record

Date deposited: 24 Aug 2011 12:17
Last modified: 18 Jul 2017 11:24

Export record

Altmetrics

Contributors

Author: Mark van Duin
Author: Annemiek Broyl
Author: Yvonne de Knegt
Author: Hartmut Goldschmidt
Author: Paul G. Richardson
Author: Wim C.J. Hop
Author: Bronno van der Holt
Author: Debora Joseph-Pietras
Author: George Mulligan
Author: Rachel Neuwirth
Author: Pieter Sonneveld

University divisions


Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×